Home > Rheumatology > Gene profiling may predict treatment response in refractory rheumatoid arthritis

Gene profiling may predict treatment response in refractory rheumatoid arthritis

Journal
Nature Medicine
Reuters Health - 03/06/2022  - In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say. "We believe this study is a paradigm shift in precision medicine in RA," Dr. Costantino Pitzalis and Dr. Myles Lewis, both of Queen Mary University of London, UK, told Reuters Health by email. "We envisage that routine use of synovial biopsies could facilitate a patient-centered approach to the management of RA, thus moving away from the current trial-and-error drug prescribing towards an emergent era in which selection of the optimal drug is based on synovial biopsy gene signatures." "The results will not directly change clinical practice immediately, as further development and additional clinical studies are needed to turn our results into a truly practical diagnostic test...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on